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PVSS for the privilege of discussing this paper, and I would like to
commend the research done by the group at Alabama looking at
the value of statins for patients who receive aneurysm repair. I
would also like to personally thank the authors for providing in
advance a copy of the manuscript.
These ﬁndings that statin use is variable across different pop-
ulations, and, additionally, that it is an independent predictor of
survival adds to the growing body of literature emphasizing the
importance of optimal medical management for patients with
surgical vascular disease. Other studies have shown that cardiovas-
cular risk reduction is not offered to many of the surgical patients
with cardiovascular disease, and perhaps this study will highlight
the importance of providing more complete care to our vascular
patients who, as a rule, have signiﬁcant coexisting disease.
I have three questions. First, your study showed improved
survival even after controlling for underlying cardiovascular
disease, suggesting that the statins may exert their effect beyondthat of reducing death associated with cardiovascular disease. Do
you think that this is likely a direct effect, or do you think that
perhaps patients receiving statins are also more likely to receive
better general care, for example, routine visits, cancer screening,
and so forth?
Second, I’m wondering if you could elaborate a little more
about the causes of death. In the manuscript, you described that
about 20% of the deaths were attributed to either aneurysm-related
causes or cardiovascular disease. How many of the remaining 80%
were due to actual other causes and for how many were the causes
not available because the deaths were collected from SSDI and
therefore unknown? Do you think having more complete informa-
tion regarding the cause of death would change your results?
My ﬁnal question is, had you considered including aneurysm
size in your analysis? Your institution has published on the feasi-
bility of repairing small aneurysms, and other authors have sug-
gested that there is a link between aneurysm size and mortality.
It might be valuable to include this variable in your analysis.
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forward to your thoughts.
Dr Gaurav M. Parmar. Thank you so much for your really
important comments.
Number one is the role of statins on abdominal aortic aneu-
rysms. It is thought that the effects of statins are through usual
atherosclerotic route by inhibiting HMG-Co-A reductase. There
are relatively fewer studies that address other pathophysiologic
mechanisms. There are a couple of clinical trials that tried to demon-
strate the pleiotropic effects of statins on aortic wall stress by using
different markers, but the evidence is iffy; it’s not conclusive.
The second point, yes, about 20% of our deaths were attrib-
uted to aneurysm or cardiovascular events. Most of the remaining
deaths either come from SSDI or are due to cancer or causes
grouped as others. I would be very happy to provide the entire
distribution of our causes of death. Using SSDI to identify deaths
is a limitation of our study, and we do not have any other way to
ascertain cause of death on those deaths. But still it is reasonable to
attribute such a large mortality beneﬁt effects to use of LMDT.
Third, aneurysm size; unfortunately, we did not look at aneu-
rysm size in this analysis. I think that is an important consideration
and we will look forward to that.Dr James Reeves (Atlanta, Ga). I have one question. How
do you at UAB handle initiating statin therapy on these patients?
Do you initiate it yourself, or do you have a vascular medicine
specialist in your department who follows these patients? If you
do initiate it yourself, how do you follow the side effects, any
adverse events, or titrate the dose?
Dr Parmar. We do have vascular medicine physicians at our
institution. As I said, we don’t know about when the lipid manage-
ment was actively initiated. It could have been initiated by the
primary care practitioner earlier, at the time of surgery by our
group, or during postoperative follow-up visits.
Dr Mark A. Patterson. Thank you Dr Reeves, as one of the
authors, I can address that.
At UAB, we have two vascular medicine physicians that assist
with perioperative and postoperative medical management. If
patients are not taking statins at the initial visit, those gentlemen
become involved, and oftentimes initiate statins. That is not me
the surgeon, but us the team. Speciﬁc communication is sent to
the primary care doctor. I must say that it is uncommon for us
to get a referral from either a UAB or outside physician, in which
the patient is not already on a statin regimen. Unfortunately, I
don’t have a speciﬁc number, but it is not very large.
